//
//
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals

Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals

Anaïs M J Møller, Jean-Marie Delaisse, Jacob B Olesen, Troels Bechmann, Jonna S Madsen, Kent Søe

First published: 15 September 2020
DOI: https://doi.org/10.1002/jbm4.10412

Zoledronic acid is a bisphosphonate commonly used to treat bone diseases such as osteoporosis and cancer-induced bone disease. Patients exhibit a variable sensitivity to zoledronic acid; the underlying explanation for this remains unclear. The objective of this study was to obtain more knowledge in this regard. We hypothesized that osteoclasts generated from different individuals would show a variable sensitivity to zoledronic acid in vitro. Osteoclasts were generated using monocytes from 46 healthy female blood donors (40 to 66 years). Matured osteoclasts were reseeded onto bone slices precoated with different concentrations of zoledronic acid. IC50 values were determined based on total eroded bone surface after 3 days of resorption. The IC50 for inhibition of osteoclastic bone resorption varied from 0.06 to 12.57μM zoledronic acid; thus, a more than 200-fold difference in sensitivity to zoledronic acid among osteoclasts from different individuals was observed. Multiple linear regression analyses showed that the determined IC50 correlated with smoking status, and the average number of nuclei per osteoclast in vitro. Further analyses showed that: (i) increasing protein levels of mature cathepsin K in osteoclast cultures rendered the osteoclasts less sensitive to zoledronic acid; (ii) surprisingly, neither the gene nor the protein expression of farnesyl diphosphate synthase was found to correlate with the IC50; and (iii) trench-forming osteoclasts were found to be more sensitive to zoledronic acid than pit-forming osteoclasts within the same cell culture. Thus, we conclude that there indeed is a high degree of variation in the potency of zoledronic acid on osteoclasts when generated from different individuals. We propose that our findings can explain some of the varying clinical efficacy of zoledronic acid therapy observed in patients, and may therefore be of clinical importance, which should be investigated in a clinical trial combining in vitro and in vivo investigations. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Recent News

4 postdoc positions to join the ERA-Net project IMMOSCAN and work on the role of immune osteoclasts in cancer – implications for therapy.
STSM and VNT call 2022 opens today. Application deadline: 2 October 2022 The applications will be evaluated by the Grant Awarding Coordinator and supported by the Grant Awarding Committee members....
Applications should be submitted at bonesecr@strutture.univaq.it and should include a detailed CV with a complete list of publications and other relevant achievements.Place of Work: University of L’Aquila, Italy, Department of...
We are seeking a highly motivated post-doctoral researcher interested in osteo-immunology to join our team and work on the diversity of osteoclasts, the multinucleated monocytic cells involved in bone resorption.We...
THREE ITC GRANTS are available for PhD students and Young Researchers and Innovators (YRI) that are WG members of GEMSTONE  from COST Inclusiveness Target Countries (ITC) and Near Neighbor Country (NNC)....
The EIC Transition 2022 (HORIZON-EIC-2022-TRANSITION-01) call, which has opened on March 1st, is intended to meet the following specific objectives: Advance, beyond the state-of-the-art, RNA delivery methods, including robust mRNA formulations, that would...